Press Releases
8/12/2010
Labopharm Reports Results for Second Quarter 2010
8/10/2010
Labopharm announces U.S. launch of OLEPTRO(TM) for treatment of major depressive disorder in adults
8/6/2010
Labopharm to present at Canaccord Genuity 30th Annual Growth Conference
7/29/2010
Labopharm to host conference call Thursday, August 12, 2010 at 8:30 A.M.(ET)
7/9/2010
Labopharm Announces Amendment to Debt Facility Agreement with Hercules
6/4/2010
Labopharm comments on judgment in Purdue appeal of decision relating to patents
5/20/2010
Labopharm announces completion of joint venture with Angelini
5/5/2010
Labopharm Reports Results for First Quarter 2010
5/5/2010
Labopharm appoints Jeffrey M. Dayno, M.D. as Chief Medical Officer
4/29/2010
Labopharm and Angelini to Establish Joint Venture to Commercialize OLEPTRO(TM) in the United States
4/26/2010
Labopharm to host conference call Wednesday, May 5, 2010 at 8:30 a.m. (ET)
4/21/2010
Labopharm Introduces INTELLITAB(TM): A Proprietary Abuse-Misuse-Deterrent Technology Platform
3/3/2010
Labopharm to present at Cowen 30th Annual Health Care Conference
2/25/2010
Labopharm Reports Results for Fourth Quarter and Fiscal Year 2009
2/19/2010
Labopharm announces underwriters' exercise of over-allotment option for recent public offering
2/18/2010
Labopharm announces closing of US$20 million public offering of units
2/16/2010
Labopharm to host conference call Thursday, February 25, 2010 at 8:30 a.m. (ET)
2/12/2010
Labopharm announces pricing of US$20 million public offering of units
2/11/2010
Labopharm announces proposed public offering of units
2/3/2010
Labopharm Receives FDA Approval For OLEPTRO(TM)
1/8/2010
Labopharm settles $1 million draw down under standby equity distribution agreement